<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00072319</url>
  </required_header>
  <id_info>
    <org_study_id>03-092</org_study_id>
    <secondary_id>P30CA008748</secondary_id>
    <secondary_id>MSKCC-03092</secondary_id>
    <nct_id>NCT00072319</nct_id>
  </id_info>
  <brief_title>Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer</brief_title>
  <official_title>Pilot Study of Epirubicin and Cyclophosphamide Followed by Paclitaxel at 10-11 Days Interval for Women With Early Breast Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pharmacia</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as epirubicin, cyclophosphamide, and paclitaxel,&#xD;
      use different ways to stop tumor cells from dividing so they stop growing or die. Giving&#xD;
      chemotherapy drugs before surgery may shrink the tumor so that it can be removed during&#xD;
      surgery. Giving chemotherapy drugs after surgery may kill any remaining tumor cells.&#xD;
&#xD;
      PURPOSE: Pilot trial to study the effectiveness of neoadjuvant or adjuvant epirubicin,&#xD;
      cyclophosphamide, and paclitaxel in treating women who have stage I, stage II, or stage III&#xD;
      breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the feasibility and safety of neoadjuvant or adjuvant epirubicin,&#xD;
           cyclophosphamide, and paclitaxel, in terms of the absence of any grade 3 or higher&#xD;
           toxicity (aside from alopecia), in women with high-risk stage I-III breast cancer.&#xD;
&#xD;
      OUTLINE: This is a pilot study.&#xD;
&#xD;
        -  Neoadjuvant or adjuvant EC therapy: Patients receive epirubicin IV over 3-5 minutes and&#xD;
           cyclophosphamide IV (EC) on day 1 and filgrastim (G-CSF) subcutaneously on days 2-9 or&#xD;
           10. Treatment repeats every 10-11 days for 4 courses in the absence of disease&#xD;
           progression or unacceptable toxicity.&#xD;
&#xD;
        -  Neoadjuvant or adjuvant paclitaxel therapy: After the completion of EC therapy, patients&#xD;
           receive paclitaxel IV over 3 hours on day 1. Patients also receive G-CSF as in EC&#xD;
           therapy. Treatment repeats every 10-11 days for 4 courses in the absence of disease&#xD;
           progression or unacceptable toxicity.&#xD;
&#xD;
      Patients who have not had prior surgery undergo definitive surgery after the completion of&#xD;
      chemotherapy. Patients also may receive adjuvant radiotherapy and/or hormonal therapy at the&#xD;
      discretion of the treating physician.&#xD;
&#xD;
      Patients are followed every 4 months for 3 years and then every 6 months for 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 11-38 patients will be accrued for this study within 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2003</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epirubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the breast&#xD;
&#xD;
               -  Stage I, II, or III&#xD;
&#xD;
               -  Inflammatory breast cancer allowed&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  SGOT/SGPT no greater than 2.5 times upper limit of normal (ULN) AND alkaline&#xD;
             phosphatase no greater than ULN OR&#xD;
&#xD;
          -  SGOT/SGPT no greater than ULN AND alkaline phosphatase no greater than 4 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  LVEF at least lower limit of normal by MUGA or echocardiogram&#xD;
&#xD;
          -  No unstable angina&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No arrhythmia requiring medical therapy&#xD;
&#xD;
          -  No myocardial infarction within the past year&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No prior allergy/hypersensitivity to any of the study drugs or other drugs formulated&#xD;
             with Cremophor EL&#xD;
&#xD;
          -  No psychiatric illness that would preclude understanding of the nature of the study or&#xD;
             study compliance&#xD;
&#xD;
          -  No active unresolved infection&#xD;
&#xD;
          -  No peripheral neuropathy greater than grade 1&#xD;
&#xD;
          -  No other nonmammary malignancy within the past 5 years except adequately treated&#xD;
             nonmelanoma skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No concurrent medical condition that would preclude study participation in the&#xD;
             judgment of the investigator&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  More than 12 months since prior immunotherapy for prior breast cancer&#xD;
&#xD;
          -  No prior or concurrent biologic therapy or immunotherapy for this breast cancer&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 12 months since prior chemotherapy for prior breast cancer&#xD;
&#xD;
          -  No prior anthracycline (i.e., doxorubicin or epirubicin) and taxane therapy&#xD;
&#xD;
          -  No prior or other concurrent chemotherapy for this breast cancer&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent hormonal therapy for chemoprevention&#xD;
&#xD;
               -  Prior hormonal therapy for chemoprevention allowed&#xD;
&#xD;
          -  No concurrent sex hormonal therapy (e.g., birth control pills or ovarian hormonal&#xD;
             replacement therapy)&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy&#xD;
&#xD;
          -  No other concurrent radiotherapy for this breast cancer&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No concurrent digitalis, beta-blockers, or calcium channel blockers for congestive&#xD;
             heart failure&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Monica N. Fornier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <study_first_submitted>November 4, 2003</study_first_submitted>
  <study_first_submitted_qc>November 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2003</study_first_posted>
  <last_update_submitted>March 1, 2013</last_update_submitted>
  <last_update_submitted_qc>March 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>inflammatory breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

